Overuse and underuse of pegfilgrastim for primary prophylaxis of febrile neutropenia

Abstract

Introduction

Guidelines recommend pegfilgrastim for primary prophylaxis of febrile neutropenia after highly myelosuppressive chemotherapy. While deviations from guidelines could result in overuse and increased costs, underuse is also a concern and could compromise quality of care. Our objectives were to evaluate guideline adherence and quantify the extent to which physician heterogeneity may influence pegfilgrastim use.

Methods

We randomly sampled 550 patients from a retrospective cohort of those who received infusions at an academic cancer center between 1 September 2013 and 1 September 2014. Electronic medical and drug dispensing records provided information on patient characteristics, chemotherapy characteristics, prescribing physician, and pegfilgrastim administration.

Results

We included 154 patients treated by 25 physicians. About half of patients were male and mean age was 61.3 years. Forty (26.1%) patients had no febrile neutropenia risk factors, 62 (40.5%) had one, and 51 (33.3%) had two or more. Thirty patients (19.5%) received pegfilgrastim, of which 12 (40%) received palliative chemotherapy. Nine (60%) of 15 patients on a regimen with a febrile neutropenia risk ≥ 20% received pegfilgrastim. Pegfilgrastim use significantly varied by cancer type (p < 0.01), chemotherapy regimen (p < 0.001), and regimen febrile neutropenia risk (p < 0.001). Multivariable analysis reaffirmed the association between chemotherapy regimen febrile neutropenia risk ≥ 20% and pegfilgrastim use (odds ratio (OR) = 10.1, 95% confidence interval (CI): 1.6–62.7) and suggested that 31% (95% CI: 8%–71%) of the variation in use was attributable to physician characteristics.

Conclusion

Pegfilgrastim was potentially overused for palliative chemotherapy and underused for chemotherapy regimens with febrile neutropenia risk ≥ 20%. Successful interventions to modify prescribing practices likely require an understanding of the relationship between specific physician characteristics and pegfilgrastim use.

Keywords

Granulocyte colony-stimulating factor chemotherapy-induced febrile neutropenia;practice patterns physicians’;pharmacy;antineoplastic combined chemotherapy protocols/adverse effects

Get full access to this article

View all access options for this article.

References

Culakova

Poniewierski

Wolff

et al.

The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study. Springerplus 2015; 4: 396–396.

Lyman

Michels

Reynolds

et al.

Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 2010; 116: 5555–5563.

Vogel

Wojtukiewicz

Carroll

et al.

First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005; 23: 1178–1184.

Sung

Nathan

Alibhai

et al.

Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007; 147: 400–411.

Kuderer

Dale

Crawford

et al.

Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007; 25: 3158–3167.

Dinan

Hirsch

Lyman

. Management of chemotherapy-induced neutropenia: measuring quality, cost, and value. J Natl Compr Canc Netw 2015; 13: e1–e7.

Smith

Khatcheressian

Lyman

et al.

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187–3205.

Smith

Bohlke

Lyman

et al.

Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2015; 33: 3199–3212.

Schnipper

Smith

Raghavan

et al.

American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol 2012; 30: 1715–1724.

10.

Crawford

Armitage

Balducci

et al.

Myeloid growth factors. J Natl Compr Canc Netw 2013; 11: 1266–1290.

11.

Aapro

Bohlius

Cameron

et al.

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47: 8–32.

12.

Langeberg

Siozon

Page

et al.

Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin’s lymphoma. Support Care Cancer 2014; 22: 2167–2175.

13.

Waters

Corrigan

Gatesman

et al.

Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic. J Oncol Pract 2013; 9: 203–206.

14.

Fagnani

Isa

Verga

et al.

Granulocyte colony-stimulating factors used in clinical practice: PoloNord registry-based cohort Italian study. Tumori 2014; 100: 491–498.

15.

Barni

Lorusso

Giordano

et al.

A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice. Med Oncol 2014; 31: 797–797.

16.

Fiegl

Steger

Studnicka

et al.

Pegfilgrastim prophylaxis in patients at different levels of risk for chemotherapy-associated febrile neutropenia: an observational study. Curr Med Res Opin 2013; 29: 505–515.

17.

Olszewski

Zullo

Nering

et al.

Use of charity financial assistance for novel oral anticancer agents. J Oncol Pract 2018; 14: e221–e228.

18.

Voog

Bienvenu

Warzocha

et al.

Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand-receptor system. J Clin Oncol 2000; 18: 325–331.

19.

Lyman

Dale

Friedberg

et al.

Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol 2004; 22: 4302–4311.

20.

Pettengell

Bosly

Szucs

et al.

Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol 2009; 144: 677–685.

21.

Lyman

Morrison

Dale

et al.

Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003; 44: 2069–2076.

22.

Lyman

Delgado

. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003; 98: 2402–2409.

23.

Lyman

Kuderer

Crawford

et al.

Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 2011; 117: 1917–1927.

24.

Shayne

Culakova

Poniewierski

et al.

Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer 2007; 110: 1611–1620.

25.

Lyman

Kuderer

. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol 2004; 50: 129–146.

26.

Lyman

Kuderer

. Epidemiology of febrile neutropenia. Support Cancer Ther 2003; 1: 23–35.

27.

Crawford

Dale

Kuderer

et al.

Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 2008; 6: 109–118.

28.

Barnes

Pathak

Schwartzberg

. G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use. Cancer Med 2014; 3: 1477–1484.

29.

Crawford

Caserta

Roila

et al.

Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol 2010. 21 Suppl 5: v248–v251.

30.

Baker

McCune

Harvey

3rd et al.

Granulocyte colony-stimulating factor use in cancer patients. Ann Pharmacother 2000; 34: 851–857.

31.

Kenna

Mahmoud

Zullo

et al.

Effect of probiotics on the incidence of healthcare-associated infections in mechanically ventilated neurocritical care patients. Nutr Clin Pract 2016; 31: 116–120.

32.

Mahmoud

Zullo

Thompson

et al.

Outcomes of protocolised analgesia and sedation in a neurocritical care unit. Brain Inj 2018; 32: 941–947.

33.

Bernens

Hartman

Curley

et al.

Assessing the impact of a targeted electronic medical record intervention on the use of growth factor in cancer patients. J Community Support Oncol 2015; 13: 113–116.

34.

Migliozzi

Zullo

Collins

et al.

Achieving blood pressure control among renal transplant recipients by integrating electronic health technology and clinical pharmacy services. Am J Health Syst Pharm 2015; 72: 1987–1992.

35.

McAuliffe

Zullo

Dapaah-Afriyie

et al.

Development and validation of a transitions-of-care pharmacist tool to predict potentially avoidable 30-day readmissions. Am J Health Syst Pharm 2018; 75: 111–119.

36.

Zullo

Gray

Holmes

et al.

Screening for medication appropriateness in older adults. Clin Geriatr Med 2018; 34: 39–54.